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Clinical Relevance 
Scientific rationale for study: A number of systematic diseases including cardiovascular disease, diabetes, 
metabolic syndrome and obesity have been associated with periodontal disease. 
Principal findings: According to existing evidence from the literature, inflammatory bowel disease seems to be 
associated with increased risk of periodontal disease and increased caries experience, although this needs to be 
confirmed by further studies. 
Practical implications: Evidence from this systematic review could guide future longitudingal studies with 
large sample sizes and more rigorous methodology, and help guide the clinical management of patients with 
inflammatory bowel disease. 
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Abstract 
Background: The objective of this systematic review was to systematically investigate whether there is an 
association between inflammatory bowel disease (IBD) and oral health. 
Methods: Literature searches for randomized and non-randomized studies were performed up to January 2017. 
Risk of bias within studies was assessed with the Downs and Black checklist. Across-studies risk of bias was 
assessed with the GRADE framework. Quantitative synthesis was conducted with random-effects meta-
analyses. 
Results: A total of 9 cross-sectional studies including 1 297 patients were included. IBD was associated with 
increased risk of periodontitis (332 more patients per 1 000 patients; 95% confidence interval: 257 to 388 
patients; p<0.001) compared to non-IBD patients. Additionally, the Decayed-Missing-Filled-Teeth index of IBD 
patients was significantly worse than non-IBD patients (mean difference: 3.85; 95% CI: 2.36 to 5.34; p=0.005). 
Patients with ulcerative colitis had considerably worse oral health for most of the assessed factors, while the 
quality of overall evidence ranged from high to low, due to observational nature of contributing studies. 
Conclusions: IBD was associated with significantly higher risk of periodontitis and worse oral health compared 
to non-IBD patients. However, longitudinal studies are needed in order to establish a causality link between IBD 
and periodontal disease. 
Registration: CRD42015019436 
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Introduction 
Rationale 
Inflammatory bowel disease (IBD) and its two major disorders, Crohn’s Disease (CD) and Ulcerative Colitis 
(CD), are a significant problem across the world, affecting about one in 200 people in developed countries and 
having a rising incidence and prevalence in developing countries (Molodecky et al. 2012). IBD is associated 
with many debilitating symptoms, including urgent diarrhoea, rectal bleeding, vomiting, anorexia, and lethargy, 
which frequently lead to poor psychosocial wellbeing with extensive consequences (Neovius et al. 2013). The 
financial burden of IBD for the healthcare system is considerable, with more than 2.2 billion US/year in the 
USA alone (Everhart & Ruhl 2009). The development and progression of IBD is considered to be based on a 
complex combination of genetic influences and environmental factors (Ellinghaus et al. 2015), where disturbed 
host-microbiome interactions likely play a significant part (Jostins et al. 2012). 
Several of these IBD-relevant factors and influences are also risk factors for periodontitis (Brandtzaeg 
2001, Kinane & Bartold 2007, Indriolo et al. 2011). In addition, studies have shown that the progression of 
disease in both IBD and periodontitis is characterized by immunoinflammatory processes and tissue destruction 
(Brandtzaeg 2001, Kinane & Bartold 2007). Finally, several other oral manifestations of IBD have been 
reported in the last decades, including oral soft-tissue lesions, cobblestoning, aphthous ulcers, lymphadenopathy, 
and pyostomatitis (Dudeney 1969, Chan et al. 1991, Scheper & Brand 2002, Harty et al. 2005). 
To this end, periodontitis has been associated with a number of systemic diseases and conditions 
including diabetes, metabolic disorder, and obesity (Chaffee & Weston 2010, Suvan et al. 2011, Nibali et al. 
2013, Papageorgiou et al. 2015a). However, to our knowledge the possible association between IBD and 
periodontitis has not yet been adequately assessed in an evidence-based manner. Such evidence could identify 
similarities between the two entities that aid in the elucidation of the underlying biological principles of IBD and 
its forms, as well as provide information about an increased global burden of care for periodontal disease 
(Petersen & Ogawa 2012) in IBD patients. 
 
Objectives 
The primary aim of this systematic review was to investigate whether the prevalence of periodontal disease is 
higher in patients with IBD compared to IBD-free patients, with the main research question being: “Do IBD 
patients have the same prevalence of periodontal disease as IBD-free patients?”. The secondary aim was to 
assess whether IBD is associated with other parameters of oral health. 
 6 
 
Methods 
Protocol and Registration 
The protocol for this systematic review was made a priori, agreed upon from all authors and registered in 
PROSPERO (CRD42015019436). This systematic review is conducted according to the Cochrane Handbook 
(Higgins & Green 2011) and reported according to the PRISMA statement (Liberati et al. 2009) and its 
extension for abstracts (Beller et al. 2013). 
 
Eligibility Criteria 
Inclusion and exclusion criteria were determined a priori (Appendix A). Both randomized controlled studies 
(RCTs) and non-RCTs that assessed any of the pre-specified periodontal or oral health outcomes in patients with 
and without IBD were included. 
 
Information Sources and Search 
Electronic general, open access, regional and grey literature databases were systematically searched up to 
January 2017 (Appendix B). MESH terms and relative keywords were used accordingly for each electronic 
database. No limitations were applied regarding publication year and status or language. The reference lists of 
included articles and relevant reviews were manually searched. Grey literature was searched through appropriate 
databases and registers. Authors were contacted when necessary for additional data or clarifications. 
 
Study Selection 
A study was judged as eligible, when none of the exclusion and all of the inclusion criteria were fulfilled. After 
removal of duplicates, articles were screened on the basis of title, abstract, and full-text. When the decision on 
the basis of title and abstract was inconclusive, the full-text article was acquired. Additional reports of the same 
trial/cohort were grouped together. When an identical study was published in more than one language, the most 
complete report was preferred, irrespective of language. Study selection was initially conducted by one author 
(SNP), who screened the titles and/or abstracts of retrieved studies. Subsequently, the full texts of potentially 
eligible studies (and from those abstracts which did not provide sufficient information to include/exclude) were 
screened by two authors independently (SNP and MH). Differences between the two authors were settled by a 
third author (JD). 
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Data Collection Process and Data Items 
Data extraction was performed independently by the same two review authors (SNP and MH) in a pre-defined 
and piloted collection form. Any disagreement was resolved by discussion with a third author (JD). Outcomes to 
be included were specified a priori at the protocol stage. All given post-treatment timepoints were to be 
included, but no such data existed. 
 
Risk of Bias in Individual Studies 
The risk of bias of RCTs was to be assessed with the Cochrane Collaboration’s tool (Higgins & Green 2011), 
but no RCTs were identified. The risk of bias of non-RCTs was assessed with a modified version of the Downs 
& Black (1998) checklist. 
 
Summary Measures and Synthesis of Results 
Data were summarized and considered suitable for pooling, if similar disease groups were reported (or could be 
formed) and the same outcomes were reported. In cases of inadequate reporting, the missing data were 
calculated or requested from the authors. Data reported as medians and interquartile ranges were converted to 
means and standard deviations. If studies reported data for CD and UC, but not for IBD collectively, data were 
pooled prior to the meta-analysis (Higgins & Green 2011). 
Mean differences (MD) for continuous outcomes and Odds Ratios (ORs) for binary outcomes, together 
with their corresponding 95% confidence intervals (CI) were calculated. A random-effects model as proposed 
by DerSimonian & Laird (1986) was chosen a priori as the primary method to estimate all pooled estimates, 
since clinical heterogeneity was expected (Papageorgiou 2014). The extent and impact of between-study 
heterogeneity was assessed by inspecting the forest plots for the localization of heterogeneity, by calculating the 
tau2 and the I² statistic, respectively, and assessing the magnitude and direction of heterogeneity. The 95% CIs 
around I2 were calculated according to the non-central χ2 approximation of Q. In case of considerable 
unexplained heterogeneity (I2 > 75%) attempts were made to achieve homogeneity and, if they failed, meta-
analysis was omitted. For meta-analyses with ≥ 3 trials, 95% prediction intervals (PrI) (Higgins et al. 2009) 
were calculated to predict effects in a future clinical setting. These incorporate observed heterogeneity in the 
meta-analysis estimates and provide a range of possible results that could exist in a future clinical setting. All 
analyses were performed in Stata version 12 (StataCorp LP, College Station, TX) with the macros metan, 
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heterogi, and metareg. All p values were 2-sided with α set at 5%, except for the test of heterogeneity, where α 
was set at 10%. No adjustment in the significance level was adopted to control for increased Type I error, since 
the nature of meta-analysis is observational per se and aims to identify existing significant associations.  
 
Risk of Bias Across Studies & Additional Analyses 
The overall quality of evidence (confidence in effect estimates) for each of the main outcomes was rated using 
the GRADE approach (Guyatt et al. 2011). For this assessment, the risk of bias of each included trial was re-
assessed separately at outcome level. The minimal clinical important, large, and very large effects for 
continuous outcomes were conventionally defined (Sloan et al. 2006) as half, one, and two standard deviations, 
respectively (and as 1.5, 2.5, and 4.3 for the odds ratio). The standard deviation for an outcome was averaged 
from the existing trials. The produced forest plots were augmented with contours denoting the magnitude of the 
observed effects. Finally, the optimal information size (i.e. required meta-analysis sample size) was calculated 
for each outcome independently for α = 5% and β = 20%. 
 Random-effects meta-regressions were conducted for the comparison of IBD compared to healthy 
patients according to the following characteristics of IBD patients (a) mean age, (b) gender (assessed through 
the male/female ratio), (c) smoking (percentage of patients smoking), (d) IBD activity (percentage of patients 
with active disease), and (e) medication use, when at least 3 studies were included. Small study effects and signs 
of publication bias were planned to be assessed, if at least ten studies contributed to the meta-analyses. 
Sensitivity analyses were planned to be conducted to check the results’ robustness according to follow-up, error 
of the method, definition of periodontitis, design of included studies (Papageorgiou et al. 2014a, Papageorgiou 
et al. 2015b), and improvement of the GRADE assessment. 
 
Results 
Study Selection 
A total of 362 and 4 papers were identified through the electronic (Appendix C) and manual searches, 
respectively (Fig. 1). After removal of duplicates and initial screening, 43 papers were judged against the 
eligibility criteria, leaving a final number of 14 included papers (Fig. 1; Appendix C; Table 1). Six publications 
(Barro 2007, Barros et al. 2008, Brito et al. 2008, Silva 2008, Figueredo et al. 2011, Brito et al. 2013), referring 
to the same study and its follow-ups, were grouped, leaving a total of 9 unique studies that were finally 
included.  
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Study Characteristics 
The characteristics of the included studies are shown in Table 1. Eight case-control studies from different 
countries were included with a total of 744 IBD patients and 553 healthy individuals. Among the IBD patients 
described in the included studies 379 of them (56%) had CD and 300 (44%) had UC. In the studies that reported 
demographic characteristics, the male/female patient distribution was balanced in the IBD and healthy groups 
(45% to 51% in the IBD and 45% to 54% in the healthy group). Likewise, the mean age across studies was 
balanced between the IBD and healthy groups (37.2 and 35.7 years). 
 
Methodological Adequacy (Risk of Bias) of Individual Studies 
The risk of bias assessment for the included studies can be seen in Table 2. Serious methodological inadequacies 
that could be associated with bias were found in four studies for at least one methodological domain. Most 
problematic domains were the use of periodontal status as a criterion for patient enrollment in the study and 
incomplete reporting of patient characteristics or statistical analyses. 
 
Results of Individual Studies and Data Synthesis 
The results of the individual studies that were not included in the meta-analyses can be found in Appendix D. 
The performed meta-analysis comparing IBD patients with healthy patients overall, CD patients with healthy 
patients, and UC patients with healthy patients are shown in Tables 3-4, Fig. 2, and Appendix E–H. Compared 
to healthy patients, patients with IBD were significantly more likely to have periodontitis (Fig. 2), had 
significantly higher % of sites with large clinical attachement loss (3 to 5 mm) higher mean pocket probing 
depth, higher periodontal treatment need, higher DMFT index, and more oral lesions. Patients with CD, 
likewise, were significantly more likely to have periodontitis, had significantly higher DMFT index, and 
significantly higher percentage of sites with pocket probing depth >3mm (Appendix G). Finally, patients with 
UC were significantly more likely to have periodontitis or oral lesions, had significantly fewer teeth (Appendix 
E), greater DMFT index (Appendix F), greater percentage of sites with clinical attachment loss >3mm, and 
greater pocket probing depth (Appendix H).  
 
Risk of Bias Across Studies 
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The risk of bias across studies (quality of evidence) according to the GRADE approach is summarized in Table 
4 and Appendix I. 
 As far as the primary outcome of this review, prevalence of periodontitis, is concerned, high quality 
evidence supported the association of IBD generally (or CD and UC separately) with increased risk of 
periodontitis. IBD was associated with a higher risk of periodontitis by 332 patients per 1000 compared to 
healthy patients. The numbers-needed-to-treat indicated that for every 3 or 4 patients screened, an additional 
patient with periodontitis would be identified, if these patients had IBD. The subtype of IBD (CD or UC) had 
also a distinct effect on oral health, with UC patients being more severely affected compared to CD patients 
(additional increase in risk by 42 per 1000 patients). 
 As far as the two secondary outcomes of number of teeth and DMFT index of patient were concerned, 
low quality evidence indicated that IBD was associated with fewer teeth per patient and higher DMFT index. 
The only reason for the low GRADE score was the fact that it was based on observational non-experimenal 
studies that provided only a snapshot picture of the disease. Patients with IBD (either CD or UC) had an average 
of one tooth less (p=0.090) and a greater DMFT index by 3.85 (p=0.005). Likewise, to the prevalence of 
periodontitis, both the number of teeth and the DMFT index were more severely affected in UC patients than in 
CD patients compared to healthy patients (Appendix G and H). This was also seen in an explorative post-hoc 
comparison between UC and CD patients, where UC patients had significantly fewer teeth, higher plaque index 
and greater attachment loss (Appendix J). 
 
Additional Analyses 
Random-effect meta-regressions according to patient characteristics failed to identify any significant modifying 
effect on periodontitis, number of teeth, and DMFT index (Appendix K). Reporting biases were planned in the 
initial protocol, but could not be performed due to the limited number of trials included in the meta-analyses. 
Sensitivity analysis according to the definition of periodontal disease was conducted by including 
studies with widely-accepted definition of periodontitis (Appendix L). This indicated that the results of the 
meta-analyses were robust in all instances. Sensitivity analysis according to the diagnostic criteria used to 
diagnose IBD, CD, and UC (Appendix M) could not be performed. Further sensitivity analyses were planned, 
but could not be conducted, due to the number and nature of the included studies 
 
Discussion 
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Summary of Evidence 
In this systematic review, the effect of IBD on periodontal disease and oral health was systematically assessed 
from eight observational clinical studies of 1 297 patients. According to the results of the meta-analyses, IBD 
was associated with a significantly increased risk of periodontitis compared to the control group, which was 
more pronounced in UC rather than in CD. 
IBD patients were significantly more likely to have periodontitis, had a higher percentage of sites with 
increased CAL, and had significantly higher mean PPD (Table 3). The included studies differed at the level of 
patient oral hygiene or the percentage of patients receiving anti-TNF therapy for IBD [6% (Barros 2007) or 40% 
(Vavricka et al. 2013)], but this was not reflected into considerable heterogeneity. The association between 
periodontitis and IBD has been attributed to common predisposing factors, such as age and genetic 
predisposition, as well as environmental or lifestyle factors (Indriolo et al. 2011). Smoking is strongly associated 
with both periodontitis (Hujoel et al. 2002) and IBD (Mahid et al. 2006), but has a distinct detrimental role for 
CD and a protective role for UC (Mahid et al. 2006). Although factors like socio-economic status and smoking, 
can confound this relationship, and indeed smokers were more heavily affected than non-smokers (Appendix 
D), adjusted ORs for confounders from included studies were consistent. Some studies have focused on the role 
of cytokines (McGee et al. 1998, Yucel-Lindberg et al. 1999) or specific pathogenic bacteria on periodontal 
destruction (Stein et al. 2010) and their alterations in IBD. In fact, it may be more useful to study the 
mechanisms explaining that the two IBD diseases are associated with periodontitis. 
A combination of genetic predisposition, environmental factors and a dysbiotic microbiota with an 
excessive host response are main etiological factors for the initiation and progression of periodontitis and 
inflammatory bowel disease (Brandtzaeg 2001, Indriolo et al. 2011). The healthy gut microbiota is mainly 
composed of strict anaerobes and dominated by Bacteroidetes and Firmicutes. Howerever, in inflammatory 
bowel disease, the relative abundance of Firmicutes and the diversity of the intestinal microbiota is greatly 
reduced (Bull & Plummer 2014, Forbes et al. 2016) The oral microbiota is almost as complex as that of the 
colon and dominated by Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes and 
Fusobacteria (Wade 2013). During the transition from periodontal health to periodontitis, the microbiota of 
periodontal pockets shifts from a predominantly Gram-positive aerobic to a predominantly Gram-negative 
anaerobic dominance (Khan et al. 2015). Periodontitis-associated species include Porphyromonas gingivalis, 
Treponema denticola, Tannerella forsythia, Aggregatibacter actinmycetemcomitans, and many others. 
However, Porphyromonas gingivalis, which has an impressive armamentarium of virulence factors, is 
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considered a “keystone pathogen”, as this bacterium can cause dysbiosis of the periodontal microbiota, which 
subsequently results in the destruction of the tooth-supporting tissues (Wade 2013, Khan et al. 2015). 
UC patients, both smokers and non-smokers, had worse oral health than CD patients, which suggests 
that the response to dental plaque may be different between these groups. Indeed, UC and CD differ regarding 
their immunopathogenesis, which involves the T helper (Th) cell differentiation; CD is considered to be a Th1 
disease while UC has characteristics of a Th2 disease (Bouma & Strober 2003). However, a direct explorative 
comparison (Appendix J) indicated that included UC patients had a significantly higher plaque index than CD 
patients, which might have confounded this effect. 
Although this was not the main scope of this systematic review, the cariological evaluation revealed 
that IBD had a higher DMFT index (3 studies; table 3; MD=3.85; p<0.05), DMF-S index (MD=7.60; p>0.05) 
(Grössner-Schreiber et al. 2006), more dentine caries (OR=2.39; p<0.05), higher Decayed index (MD=1.57; 
p<0.05) (Ślebioda et al. 2011), and more oral lesions (OR=7.90; p<0.05) than non-IBD patients. This is in 
accordance with previous reports (Sundh & Hultén 1982, Rooney 1984) and could be attributed to nutrional 
behavioural changes and alterations in salivary and microbiologic conditions in the oral cavity (Grössner-
Schreiber et al. 2006). CD patients have been reported to have an increased intake of refined carbohydrates 
compared to normal (Schütz et al. 2003) and to prefer sugary to fatty foods, due to its digestability and the 
concurrently less gastrointestinal symptoms (Järnerot et al. 1983), Additionally, it has been shown that although 
CD patients have normal saliva flow rate and buffer capacity, the number of salivary mutans streptococci and 
lactobacilli is higher than normal (Järnerot et al. 1983). The combination of these two findings might explain the 
increased caries experience of IBD patients, although other studies disagree (Halme et al. 1993, Meurman et al. 
1994). 
 Additionally, intraoral manifestations, including oral lesions, hairy tongue, ulcers, linea alba, and 
recurrent aphthous stomatitis were more evident both in the composite IBD group, and in the separate CD or UC 
groups, compared to non-IBD patients (Tables 3; Appendix D, G, and H), which could additionally hamper oral 
hygiene. 
 
Strengths and Limitations 
The strengths of the present review include the pre-defined protocol and outcomes (with deviations from it 
noted separately in Appendix N), the extensive literature search, and the strict methodology implemented during 
every stage of it, according to existing evidence-based guidelines. As both university and hospital settings were 
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included, no specific inclusion criteria were adopted and the included studies were observational of nature, the 
results could be broadly be generalized to the average patient. 
Nevertheless, only a limited number of studies was identified assessing certain outcomes and some of 
them had uneven samples of IBD and non-IBD patients. Heterogeneity could not be explained in some cases 
due to the limited number of studies, while publication bias diagnostics and sensitivity analyses could not be 
performed, which might pose a threat to the results’ validity (Papageorgiou 2014b, Papageorgiou et al. 2015c). 
Additionally, a large number of outcomes reported from included studies were included in the systematic 
review, but not in the meta-analyses, as only one study contributed to their analysis (Appendix D). It is possible 
that some significant differences reported by them correspond to actual differences between IBD and non-IBD 
patients. These can be evaluated in a future update of this review, if additional studies are included. Moreover, 
although this was not possible to evaluate in this review due to the limited information provided, it would be 
interesting to know in which cases the diagnosis of perdiodontal disease preceeds IBD or the other way around. 
Finally, the biggest limitation of this study is that only cross-sectional studies were included, which provide a 
snapshot picture of the evidence and cannot support a causality between IBD and periodontitis or vice versa. 
 
Conclusion 
According to high quality evidence originating from cross-sectional studies, inflammatory bowel disease is 
significantly associated with increased risk of periodontal disease. Additionally, low quality evidence from 
cross-sectional studies indicates that patients with inflammatory bowel disease have significantly greater caries 
experience compared to healthy patients. 
Although considerable indications of impaired oral health in inflammatory bowel disease were found from 
this systematic review, this was based on cross-sectional studies of observational nature, which provide a 
“snapshot-picture” of a possible underlying pathology. Well-designed prospective controlled longitudinal 
studies of patients with/without inflammatory bowel disease and periodontitis are direly needed, in order to 
evaluate the impact of inflammatory bowel disease on oral health and its interrelation with tissue response to 
periodontic treatment. 
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Tables 
Table 1. Characteristics of included studies 
Nr. Study 
Design; setting; 
language 
Patients (no; M/F; mean age) 
Extras (ethnicity; smoking; 
hypertension; diabetes) 
IBD Perio Oral Inter 
1 
Barros 
collated$ 
CC; University; 
Brazil; EN/POR 
IBD: 179 (64/115) pts; 40.9 yrs 
Ctr: 74 (24/50) pts; 40.3 yrs 
53% Caucasian, 37% mixed, 
9% African; 38% smokers; 
14% hypertension; 1% 
diabetes 
CD: 99 (31/68) pts; 39.0 yrs; 22% 
active; extraintestinal 51% 
UC: 80 (33/47) pts; 43.3 yrs; 24% 
active; extraintestinal 53% 
Periodontitis (at least 4 x 
CAL≥3mm); %PI; %BOP; 
PPD; CAL; %CAL≥3mm; IL-
18; IL-1β; IL-4; IL-6; IFN-γ; 
various bacteria 
#Teeth; 
DMFT; 
91% of CD pts 
and 100% of UC 
pts receiving 
medication 
2 
Groessner-
Schreiber et al. 
(2006) 
CC; 
University/private 
practice; 
Germany; EN 
IBD: 62 (24/38) pts; 38.4 yrs 
Ctr: 59 (24/35) pts; 38.2 yrs 
100% Caucasian; 45% 
smokers 
CD: 46 pts; 39% active 
UC: 16 pts; 25% active 
Overall  
%PI; %BOP; PPD; 
%CAL≥4mm; %CAL≥5mm 
#teeth; 
DMFS; 
dentine 
caries 
All IBD 
receiving 
medication 
3 
Habashneh et 
al. (2012) 
CC; University; 
Jordan; EN 
IBD: 160 (94/66) pts; NR 
Ctr: 100 (62/38) pts; NR 
70% smokers; 11% 
hypertension 
CD: 59 (33/26) pts 
UC: 101 (61/40) pts 
Periodontitis; PI; GI; PPD; 
CAL; GR; %BOP; %PPD≥3; 
%PPD≥4; %CAL≥3; 
%CAL≥4; %CAL≥5 
- - 
4 
Koutsochristou 
et al. (2015 
CC; University; 
Greecel EN 
IBD: 55 (25/30) pts; 12.3 yrs 
Ctr: 55 (25/30) pts; 12.2 yrs 
0% smokers 
CD: 36 (18/18) pts 
UC: 19 (7/12) pts 
Periodontal treatment need 
(CPITN 2-3); %GI; %PI 
DMFT 
All IBD 
receiving 
medication 
5 
Rathnayake 
(2008) 
 CC; University; 
Sweden; EN 
IBD: 30 (15/15) pts; 41.6 yrs 
Ctr: 15 (7/8) pts; 42.1 yrs  
 49% Caucasian, 44% mixed, 
7% black; 13% smokers; 13% 
hypertension; 0.2% diabetes 
 CD: 15 (8/7) pts; 38.2 yrs 
UC: 15 (7/8) pts; 45.0 yrs 
31% extra-intestinal 
manifestations; 18% active 
disease 
%PI; %BOP; PPD; CAL; 
%CAL ≥3mm; %CAL ≥4mm; 
GCF volume; IL-18; IL-12; 
 #teeth; 
96% receiving 
medications 
6 
Ślebioda et al. 
(2011) 
CC; University; 
Poland; EN/PL 
IBD: 95 (53/42) pts; 37.3 yrs 
Ctr: 70 (24/46) pts; 31.6 yrs 
No systematic diseases 
CD: 70 (37/33) pts; 37.4 yrs 
UC: 25 (16/9) pts; 37.2 yrs 
Periodontal treatment need 
(CPITN 2-3) 
#teeth; 
DMFT; 
OHI 
- 
7 
Van Dyke et 
al. (2013)* 
CC; University; 
USA; EN 
IBD:20 (NR) pts; NR yrs 
Ctr: 20 (NR) pts; NR yrs 
Smoking up to 10 cg/day  
 (Only for the IBD & PD 
subgroup) 
CD: 6 (NR) pts; NR yrs 
UC 4 (NR) pts; NR yrs 
Redness; BOP; CAL; CF-
PGE2 levels 
 - 
50% taking 
steroids 
8 
Vavricka et al. 
(2013) 
CC; University; 
Switzerland; EN 
IBD: 113 (65/48) pts; 40.6 yrs 
Ctr: 113 (58/55) pts; 41.7 yrs 
58% smokers 
CD: 69 (37/32) pts; 39.6 yrs 
UC: 44 (28/16) pts; 42.3 yrs 
PPD; CAL; CAL at deepest 
pocket; %BOP; %PBI 
DMFT 
About 73% 
receiving 
medication and 
36% had surgery 
9 
Zervou et al. 
(2007) 
CC; state hospital; 
Greece; EN 
IBD: 30 (NR) pts; 40.0 yrs 
Ctr: 47 (NR) pts; 43.0 yrs 
- 
CD: 15 pts 
UC: 15 pts 
Overall 67% active 
Periodontitis; gingivitis; 
gingival bleeding 
- 
80% receiving 
medication 
*various non-periodontal outcomes relating to IBD microbiota, neutrophil chemotaxis, phagocytosis, inhibition of neutrophil function were omitted. 
$Including 6 studies (Barro 2007, Barros et al. 2008, Brito et al. 2008, Silva 2008, Figueredo et al. 2011, Brito et al. 2013). 
M/F, male/female; IBD, inflammatory bowel disease; CC, case-control; EN, English; POR, Portuguese; Ctr, control; pts, patients; yrs, years; CD, Crohn’s disease; UC, ulcerative 
colitis; CAL, clinical attachment loss; PI, plaque index; BOP, bleeding on probing; PPD, pocket probing depth; IL, interleukin; IFN, interferon; DMFT, decayed-missing-filled-teeth 
index; DMFS, decayed-missing-filled-surfaces index; GI, gingival index; GR, gingival recession; GCF, gingival crevicular fluid; PL, Polish; CPITN, community periodontal index of 
treatment need; OHI, oral health index; NR, not reported; CF-PGE2, prostaglandin E2 in gingival crevicular fluid; PBI, papilla bleeding index. 
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Table 2. Methodological inadequacies associated with risk of bias within the included studies 
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Was selection of IBD and non‐IBD patients drawn from the same population and over the same period?       
 
          
Can we be confident that IBD patients had IBD?       
 
          
Can we be confident that non-IBD patients had no IBD?       
 
          
Can we be confident that presence/absence of periodontal disease was not used as a patient selection criterion?       
 
          
In
te
rn
al
 v
al
id
it
y
 
Are the characteristics of the patients included in the study clearly described ?       
 
          
Did the study match IBD and non-IBD patients for all variables that are associated with periodontal health (age, gender, smoking, diabetes) or did the statistical 
analysis adjust for these prognostic variables? 
      
 
          
Can we be confident in the assessment of periodontal disease (outcome measures valid and reliable)?       
 
          
R
ep
o
rt
in
g
 
Is reporting of results complete and transparent (for continuous outcomes: n, mean, SD; for binary outcomes: sample and events; for calculated effect sizes: point 
estimate and SE or 95% CI) 
      
 
          
Were the statistical tests used to assess the main outcomes appropriate (normality/pairness)?       
 
          
Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?       
 
          
           
 Definitely yes (low risk of bias)           
 Probably yes          
 Not possible (unclear)          
 Probably no          
 Definitely no (high risk of bias)          
$Including 6 studies (Barro 2007, Barros et al. 2008, Brito et al. 2008, Silva 2008, Figueredo et al. 2011, Brito et al. 2013). 
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Table 3. Results of meta-analyses comparing patients with inflammatory bowel disease (combined Crohn’s disease and ulcerative colitis) compared to healthy patients 
 
  Effect size  Heterogeneity 
Outcomes Studies MD, SMD, or OR (95% CI) p 95% PrI 
 
I2 (95% CI) τ2 
Primary outcome        
Periodontitis 4 OR: 4.55 (3.00,6.91) <0.001 1.83,11.36  0 (0,68) 0 
        
Secondary outcomes        
Number of teeth 4 MD: -1.00 (-2.15,0.16) 0.090 -5.30,3.31 
 
48 (0,81) 0.656 
DMFT index 4† MD: 3.85 (2.36,5.34) <0.001 -2.54,10.24 
 
74 (0,89) 1.626 
Plaque index # 
      
Gingival index 2‡ SMD: 1.19 (0.75,1.63) <0.001 NA  71 (NA) 0.073 
Bleeding on probing 4 MD: 1.90 (-3.21,7.01) 0.466 -19.10,22.91 
 
69 (0,87) 17.033 
Clinical attachment loss a 
      
Clinical attachment loss > 3mm 2 MD: 8.88 (1.48,16.27) 0.019 NA 
 
52 (NA) 15.535 
Clinical attachment loss > 4mm 2 MD: 11.52 (1.82,21.23) 0.020 NA  68 (NA) 34.435 
Clinical attachment loss > 5mm 2 MD: 3.72 (1.84,5.60) <0.001 NA  0 (NA) 0 
Pocket probing depth 3b,* MD: 0.63 (0.16,1.10) 0.008 -5.37,6.63 
 
97 (94,98) 0.165 
Pocket probing depth > 3mm 2 MD: 0.10 (-2.75,2.94) 0.948 NA 
 
0 (NA) 0 
Pocket probing depth > 4mm 3c,* MD: -3.45 (-10.46,3.55) 0.334 -88.64,81.74 
 
94 (NA) 32.178 
Periodontal treatment need (CPITN 2-3) 2 OR: 6.10 (2.50,14.93) <0.001 NA  60 (NA) 0.255 
Oral lesions 3* OR: 7.90 (1.46,42.61) 0.016 0, >109 
 
93 (80,96) 1.756 
Angular cheilitis 2 OR: 8.26 (0.53,128.31) 0.131 NA 
 
65 (NA) 2.635 
Aphthous lesions 3 OR: 2.45 (1.18,5.12) 0.017 0.00,1 829.56  29 (0,80) 0.130 
Hairy tongue 2 OR: 8.01 (0.97,66.33) 0.054 NA  0 (NA) 0 
Ulceration 2 OR: 9.10 (1.12,74.28) 0.039 NA  0 (NA) 0 
MD, mean difference; OR, odds ratio; CI, confidence interval; PrI, predictive interval; NA, not applicable; DMFT, decayed missing filling teeth; CPITN, Community 
Periodontal Index of Treatment Needs. 
#Standardized Mean Difference (SMD) used instead of MD to combine two different plaque indeces (O Leary index and Sillness index); meta-analysis omitted due to 
heterogeneity: 5 studies highly dispersed on both sides (SMD=0.12; 95% CI=-0.29,0.52; P=0.579; I2=86%); omission of a single trial not feasible. 
*extreme heterogeneity, but agrees on direction; effect magnitude might be imprecise.  
†moderate to high heterogeneity, but agrees on direction and the calculated inconsistency (I2) has large uncertainy interval 0% to 89%; meta-analysis judged as safe .  
a Meta-analysis omitted; three studies with extreme heterogeneity; studies evenly distributed (MD=0.23; 95% CI=-0.25,0.71; p=0.349; I2=87). 
b Omitted study of Groessner-Schreiber et al. (2006) due to homogeneity; results might be unstable (original: MD=0.46; 95% CI=0.04,0.87; p=0.030; I2=97). 
c Omitted study of of Groessner-Schreiber et al. (2006) due to homogeneity; results might be unstable (original: MD=-2.20; 95% CI=-7.31,2.91; p=0.399; I2=90). 
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Table 4. Summary of findings table with the risk of bias assessment across studies (GRADE approach) 
Patients: patients of any age, sex or ethnicity 
Settings: university clinics (Brazil, Greece, Jordan, Switzerland) and state hospital (Greece) 
Intervention (exposure): inflammatory bowel disease (Crohn's disease and ulcerative colitis) 
Comparison: control (no inflammatory bowel disease) 
Outcomes Illustrative comparative risks/changes (95% CI) 
Patients 
(trials) 
GRADE Comments 
  IBD-free patients IBD patients   
 
  
  Assumed risk per 1 000 patients (range) Corresponding risk per 1 000 patients (95% CI)   
 
  
Periodontitis       
 
  
IBD 468 patients per 1 000 (range 0 to 797) 
332 more patients per 1 000 (257 to 388 more) compared 
to healthy patients. 
811 (4) 
High1,2 
⊕⊕⊕⊕ 
NNT=4 (3 to 4) 
CD   
309 more patients per 1 000 (211 to 384 more) compared 
to healthy patients. 
572 (4) 
High2,3 
⊕⊕⊕⊕ 
NNT=4 (3 to 5) 
UC   
351 more patients per 1 000 (252 to 421 more) compared 
to healthy patients. 
508 (3) 
High1,2 
⊕⊕⊕⊕ 
NNT=3 (3 to 4) 
      
 
Assumed levels (range) Corresponding levels (95% CI) 
   
Number of teeth 
  
  
 
  
IBD 25.14 teeth (range 23.70 to 26.72) 
Decrease by 1.00 teeth (2.15 decrease to 0.16 increase) 
compared to healthy patients. 
578 (4) 
Low 
⊕⊕⊖⊖ 
  
CD   
Decrease by 0.11 teeth (1.52 decrease to 1.31 increase) 
compared to healthy patients. 
381 (3) 
Low 
⊕⊕⊖⊖ 
  
UC   
Decrease by 1.86 teeth (0.04 to 3.68 decrease) compared 
to healthy patients. 
337 (3) 
Low 
⊕⊕⊖⊖ 
  
      DMFT index 
     
IBD 7.70 (range 2.04 to 12.50) 
Increase by 3.85 (2.36 to 5.34 increase) compared to 
healthy patients 
749 (4) 
Low 
⊕⊕⊖⊖  
CD 
 
Increase by 3.73 (0.70 to 6.75 increase) compared to 
healthy patients 
491 (3) 
Low 
⊕⊕⊖⊖  
UC   
Increase by 3.97 (1.94 to 6.00 increase) compared to 
healthy patients 
402 (3) 
Low 
⊕⊕⊖⊖ 
  
All judgements start from “low”, due to the vast inclusion of non-randomized studies. 
1Rated up by two levels for very large effect included in the confidence and predictive interval. 
2Rated up by one; estimates adjusted for confounders confirmed results agree with original analyses. 
3Rated up by one level for large effect included in the confidence and predictive interval. 
CI, confidence interval; IBD, inflammatory bowel disease; NNT, number needed to treat; CD, Crohn’s disease; UC, ulcerative colitis. 
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Figure Legends 
Fig. 1. Flow diagram that depicts the workflow of identifying qualifying studies. 
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Fig. 2. Forest plot with the meta-analyses regarding the prevalence of periodontitis. IBD, inflammatory bowel disease; n, affected patients; N, sample; OR, odds ratio; CI, 
confidence interval; adj, adjusted estimates; PrI, predictive interval; CD, Crohn’s disease; UC, ulcerative colitis. 
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Appendix S1 - Eligibility criteria used in this systematic review according to the PICOS approach. 
 
Characteristic Inclusion criteria Exclusion criteria 
Observational analysis (prevalence of periodontitis) 
Patients Patients of any age or sex - 
Intervention 
(here 
exposure) 
Diagnosis of some type of IBD. No patients with some type of IBD. 
Comparison Absence of IBD. No comparison with IBD-free patients. 
Outcome 
Periodontal health. 
Primary outcome: periodontitis. 
Secondary outcomes: any outcome pertaining to (a) clinical periodontal outcome, 
(b) markers of periodontal inflammation. 
Absence of periodontal outcomes. 
Study design 
Studies of observational nature are eligible for this analysis. If provided, 
prevalence data will be also included from RCTs. Any clinical setting will be 
included. 
Animal studies and non-clinical studies will be excluded. 
Interventional analysis (effect of periodontal or IBD treatment) 
Characteristic Inclusion criteria Exclusion criteria 
Patients Patients of any age or sex with IBD and/or periodontal disease. - 
Intervention Any kind of intervention addressing the periodontal disease or the IBD. 
No intervention addressing the periodontal disease or the 
IBD. 
Comparison 
Comparison of patients similar to the intervention/exposure group, but without 
IBD. 
 
Outcome 
Same types of outcomes as in Table S1a. 
Eligible outcomes include assessing periodontal disease outcomes before & after 
treatment for the IBD or IBD disease outcomes before &,after treatment for the 
periodontal disease 
No association of periodontal or IBD treatment with the 
outcomes of the other disease. 
Study design 
Both randomized and non-randomized controlled human trials will be included 
(Papageorgiou et al. 2014). If serious methodological discrepancies between the 
two study designs are found (Papageorgiou et al., 2015), they will be assessed 
separately. Any clinical setting will be included. 
Animal studies, clinical non-interventional and non-clinical 
studies will be excluded. 
IBD, inflammatory bowel disease; RCT, randomized controlled trial. 
 
Appendix S2. Search strategies used for each database with the corresponding results (last search Jan 2017). 
 
Electronic database Search strategy used Limits 
Hits up to 
May 2015 
Update up 
to Jan 2017 
General sources        
CDSR searched via Cochrane Library 
www.thecochranelibrary.com 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR 
“Crohn’s disease” OR “Crohn disease”) 
All text 1 1 
CENTRAL searched via Cochrane Library 
www.thecochranelibrary.com 
DARE searched via Cochrane Library 
www.thecochranelibrary.com 
MEDLINE (MeSH Terms) searched via PubMed 
www.ncbi.nlm.nih.gov/sites/entrez/ 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR 
“Crohn’s disease” OR “Crohn disease”) 
Limit to humans 91 16 
Scopus 
www.scopus.com 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR 
“Crohn’s disease” OR “Crohn disease”) 
Title/abstract/keywords 
Limit to dentistry 
44 6 
Open access sources        
DOAJ  
http://www.doaj.org/ 
-“inflammatory bowel disease” AND periodon* 
-Crohn AND periodon* 
-“ulcerative colitis” AND periodon* 
All fields 6 0 
Regional sources        
VHL 
http://regional.bvsalud.org/php/index.php?lang=en 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR Crohn) Exclude MEDLINE and CENTRAL 16 1 
Scielo 
http://www.scielo.org/php/index.php?lang=en 
("inflammatory bowel" OR Crohn OR "ulcerative colitis") AND periodon* - 0 0 
Grey literature sources        
Digital Dissertations searched via UMI/ProQuest 
http://proquest.umi.com/login 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR 
“Crohn’s disease” OR “Crohn disease”) 
Limit to Dentistry 54 8 
German National Library of Medicine (ZB MED) 
http://www.medpilot.de 
("inflammatory bowel" OR Crohn OR "ulcerative colitis") AND periodon* 
Limit to Medizin/Gesundheit 
Exclude MEDLINE, Books 
5 0 
ISI Web of Knowledge 
http://apps.webofknowledge.com/ 
periodon* AND (“inflammatory bowel” OR “ulcerative colitis” OR 
“Crohn’s disease” OR “Crohn disease”) 
Topic 
Limit to Dentristry oral surgery 
medicine 
112 0 
WHO trial search portal 
http://apps.who.int/trialsearch/ 
("inflammatory bowel" OR Crohn OR "ulcerative colitis") AND periodon* - 0 0 
OpenSIGLE 
http://www.opengrey.eu/ 
("inflammatory bowel" OR Crohn OR "ulcerative colitis") AND periodon* - 1 0 
Overall articles from electronic search   330 32 
$ Highly-sensitive search strategy tested, in all databases, but included too few results and was omitted in many databases. 
BBO, Bibliografia Brasileira de Odontologia; CDSR, Cochrane Database of Systematic Reviews; CENTRAL, Cochrane Central Register of Controlled Trials; DARE, Database of 
Abstracts of Reviews of Effects; DOAJ, Database of Open Access Journals; ISI, Institute for Scientific Information; LILACS, Literatura Latino-Americana e do Caribe em 
Ciências da Saúde; MeSH, Medical Subject Headings; Scielo, Scientific Eletronic Library on line; UMI, University Microfilms International; WHO, World Health Organization. 
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Appendix S3. List of excluded/included studies. 
 
Nr. Paper 
 
1 
Acharya AAMDPSTKY. Developing an electronic dental record information model for 
general dentistry [3416882]: University of Medicine and Dentistry of New Jersey; 2010. 
Excluded by title 
2 
Alasqah MAZDY. Salivary Biomarkers of Periodontal Disease in Smoker and Non-Smoker 
Periodontitis Patients [1555895]: Tufts University School of Dental Medicine; 2014. 
Excluded by title 
3 
Albilia JATHY. Serum BMP-2, 4, 7 and AHSG in Patients with Heterotopic Ossification 
Following Arthroplasty [Mr82350]: University of Toronto (Canada); 2011. 
Excluded by title 
4 
Bhatt AALAY. Mesenchymal stem cells from human gingiva ameliorate murine alimentary 
mucositis [1496953]: University of Southern California; 2011. 
Excluded by title 
5 
Calhoun CCACRY. Cellular functions of cyclophilin A in actin stability and cyclosporine A 
induced-gingival overgrowth [3356521]: University of California, Los Angeles; 2008. 
Excluded by title 
6 
Champaiboon CAHMCY. Calprotectin S100A9 structural domains regulate epithelial cell 
resistance to bacterial invasion [3338934]: University of Minnesota; 2008. 
Excluded by title 
7 
Chino TACEAY. Regulation of inflammation and homeostatsis of oral mucosal tissue by 
dendritic cells [3345634]: University of Washington; 2008. 
Excluded by title 
8 
Chou C-HADSRSMY. Association of Selected Candidate Gene Polymorphisms with 
Periodontal Disease [3483535]: University of Medicine and Dentistry of New Jersey; 2011. 
Excluded by title 
9 
Divaris KAOAFY. Exploring the genetic basis of chronic periodontitis: A genome-wide 
approach [3495471]: The University of North Carolina at Chapel Hill; 2011. 
Excluded by title 
10 
El-Awady AACCY. Porphyromonas gingivalis Escape-from Autophagy in Human Myeloid 
Dendritic Cells via Minor Mfa-1 Fimbra-DC-Sign Interactions [3579936]: Georgia Regents 
University; 2014. 
Excluded by title 
11 
Eskan MAY. Age-associated changes in innate immunity and their impacts on 
inflammatory disease [3502286]: University of Louisville; 2011. 
Excluded by title 
12 
Fiedler LY. Role of decorin in control of endothelial cell behaviour [U584185]: Cardiff 
University (United Kingdom); 2007. 
Excluded by title 
13 
Fleming PPABPHY. The effects of 2-DeNT oral topical powder on minor recurrent 
aphthous ulcers [1539091]: The Texas A&M University System Health Science Center; 
2013. 
Excluded by title 
14 
Fredman GBAVDTEY. Resolvin E1 regulation of platelet functions: Novel pathways in 
resolution [3357646]: Boston University; 2009. 
Excluded by title 
15 
Freire MAZHHY. Antibody mediated osseous regeneration [3513760]: University of 
Southern California; 2012. 
Excluded by title 
16 
George JASDY. Cigarette smoke promotes genomic evolution in the periodontal pathogen 
Porphyromonas gingivalis [1527649]: University of Louisville; 2013. 
Excluded by title 
17 
Ghadiri JAAOCCY. The prevalence of the uncultivated bacterium TM7a in human 
subgingival plaque [1547092]: San Jose State University; 2013. 
Excluded by title 
18 
Hitimana HY. The Association between Functional Foods and Dental Caries Experience 
[Mr67042]: McGill University (Canada); 2009. 
Excluded by title 
19 
Horst OVAD-CBAY. Defense mechanisms in human tooth pulp: Odontoblast functions 
[3328407]: University of Washington; 2008. 
Excluded by title 
20 
Jaffray ECY. Characterisation of paediatric odontogenic bacteraemia [U591972]: 
University of London, University College London (United Kingdom); 2006. 
Excluded by title 
21 
Lenga YY. Osteopontin expression is required for myofibroblast differentiation [Mr44972]: 
University of Toronto (Canada); 2008. 
Excluded by title 
22 
Loner CMY. Click scaffolds for the inhibition of Porphyromonas gingivalis and 
Streptococcus gordonii biofilm formation [1521240]: University of Louisville; 2012. 
Excluded by title 
23 
Ma WAFSJY. Carbohydrate receptors, preterm labor, and periodontitis [3412216]: 
University of California, San Francisco; 2010. 
Excluded by title 
24 
Maria OY. Identification and characterization of a cell source to regenerate salivary glands 
[Nr72686]: McGill University (Canada); 2010. 
Excluded by title 
25 
McLean-Plunkett EAAMAEY. Vitamin D and Calcium Intake and the Prevalence of 
Periodontal Disease in Postmenopausal Women [1519937]: State University of New York 
at Buffalo; 2012. 
Excluded by title 
26 
Nibali LY. Analysis of genetic polymorphisms as risk factors for Aggressive Periodontitis 
[U592181]: University of London, University College London (United Kingdom); 2006. 
Excluded by title 
27 Noueihed CY. An investigation of the effect of neighbourhood characteristics on traumatic Excluded by title 
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dental injuries among a sample of Quebec children [Mr56862]: McGill University 
(Canada); 2009. 
28 
Odusanwo OAABOJY. Resolvin D1 prevents TNF-alpha-mediated disruption of salivary 
epithelial formation [1500493]: State University of New York at Buffalo; 2011. 
Excluded by title 
29 
Oluwadara OOACFY. Molecular Biomarker Profiling and Translational Evidence-Based 
Dentistry in Oral Lichen Planus and Oral Squamous Cell Carcinoma [3446847]: University 
of California, Los Angeles; 2010. 
Excluded by title 
30 
Paes Batista da Silva AAOSY. Bacterial Characterization in Health and Periodontal 
Diseases During Induced Gingival Inflammation [1513063]: The University of North 
Carolina at Chapel Hill; 2012. 
Excluded by title 
31 
Paes Batista da Silva AY. Role of Osteopontin During Dextran Sulfate Sodium-induced 
Colitis [Nr67676]: University of Toronto (Canada); 2009. 
Excluded by title 
32 
Papathanasiou EAGTTTCY. Levels of interferon-gamma (IFN-gamma), interleukin-4 (IL-
4), interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP) in gingival crevicular 
fluid from patients with chronic periodontitis [1514563]: Tufts University School of Dental 
Medicine; 2012. 
Excluded by title 
33 
Park MSMY. Oral health status in children undergoing treatment for neutropenia 
[Mr76204]: University of Toronto (Canada); 2011. 
Excluded by title 
34 
Patil CSAKKLY. Targeting mRNA stability as a potential therapeutic for LPS-induced 
inflammatory bone loss [3344637]: State University of New York at Buffalo; 2007. 
Excluded by title 
35 
Phattarataratip EABJAY. The role of salivary antimicrobial peptides in shaping 
Streptococcus mutans ecology [3422183]: The University of Iowa; 2010. 
Excluded by title 
36 
Phillips CRAKKBY. A qualitative survey of orthodontic extraction related patient 
information available on the World Wide Web [1585315]: Saint Louis University; 2014. 
Excluded by title 
37 
Pongpichit BY. The prevalence and extent of school absences and factors related to 
absences caused by dental conditions and dental care in Thai schoolchildren [U593118]: 
University of London, University College London (United Kingdom); 2006. 
Excluded by title 
38 
Prakasam SACCY. Modulating immune responses of Langerhans cells against microbial 
associated molecular patterns [3401725]: State University of New York at Stony Brook; 
2009. 
Excluded by title 
39 
Sahli MWAMAEY. The association between plasma 25-hydroxyvitamin D concentration 
and oral bacteria among postmenopausal women [1519952]: State University of New 
York at Buffalo; 2012. 
Excluded by title 
40 
Scheller ELAKPHY. Regulation of bone formation and pathology by local actions of leptin 
in the bone marrow [3493053]: University of Michigan; 2011. 
Excluded by title 
41 
Schwarzberg KAKSTY. Oral polymicrobial communities and impact on human health 
[3609026]: San Diego State University; 2013. 
Excluded by title 
42 
Sculley DVY. Inter-individual variation in saliva antioxidant status in relation to periodontal 
disease [U191563]: University of Leicester (United Kingdom); 2004. 
Excluded by title 
43 
Seif MMAJS-JY. Etiopathology of autoimmune disease and dental perspectives 
[1559614]: Boston University; 2014. 
Excluded by title 
44 
Seville LY. Study of tetracycline resistance determinants and their genetic supports in the 
oral and faecal metagenomes of six European countries [U592369]: University of London, 
University College London (United Kingdom); 2007. 
Excluded by title 
45 
Shapiro JLAPMLY. The endocytosis of enamel matrix protein derivatives [3368646]: 
University of Southern California; 2009. 
Excluded by title 
46 
Shrestha DAYPY. Implementing Teledentistry in Nepal: Using Mobile Phone and Internet 
as Store-and-Forward Method [1507181]: University of California, Davis; 2011. 
Excluded by title 
47 
Singer JAAJSY. Vitamin D and chronic pain: A comprehensive review [1545731]: Temple 
University; 2013. 
Excluded by title 
48 
Villoria PAHVY. A clinical study to assess effect of oral hygiene with a probiotic organism 
on dental plaque pH and on plaque bacteria including Streptococcus mutans [1546977]: 
State University of New York at Buffalo; 2013. 
Excluded by title 
49 
Yezdani GAZPY. Role of VDR in host immune response to Porphyromonas gingivalis 
infection [1499774]: The University of Alabama at Birmingham; 2011. 
Excluded by title 
50 
Zhang GARJDY. Streptococcus cristatus modulates epithelial innate immune response 
through regulating nuclear factor-kappa B pathway [3389387]: University of Minnesota; 
2009. 
Excluded by title 
51 Zhang SAOSY. Regulation of Inflammatory Genes Involved in Periodontal Diseases by Excluded by title 
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DNA Methylation [3464948]: The University of North Carolina at Chapel Hill; 2011. 
52 
Zhang SAOSY. Expression of interleukin-37 (IL37) and the genetic variations of IL37 in 
relation to chronic periodontitis [1557234]: The University of North Carolina at Chapel Hill; 
2014. 
Excluded by title 
53 
Abo T, Kawamura T, Kawamura H, Tomiyama-Miyaji C, Kanda Y. Relationship between 
diseases accompanied by tissue destruction and granulocytes with surface adrenergic 
receptors. Immunologic research. 2007;37(3):201-10. Epub 2007/09/18. 
Excluded by title 
54 
Ayangco L, Rogers RS, 3rd, Sheridan PJ. Pyostomatitis vegetans as an early sign of 
reactivation of Crohn's disease: a case report. J Periodontol. 2002;73(12):1512-6. Epub 
2003/01/28. 
Excluded by title 
55 
Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 
cytokines and their role in destructive inflammatory disorders. Clinical and experimental 
immunology. 2007;149(2):217-25.  
Excluded by title 
56 
Castellanos JL. [Periodontal immunopathology]. Revista ADM : organo oficial de la 
Asociacion Dental Mexicana. 1985;42(5):149-54. Epub 1985/09/01. Immunopatologia 
parodontal. 
Excluded by title 
57 
Chi AC, Neville BW, Krayer JW, Gonsalves WC. Oral manifestations of systemic disease. 
American family physician. 2010;82(11):1381-8.  
Excluded by title 
58 
Diegelmann J, Czamara D, Le Bras E, Zimmermann E, Olszak T, Bedynek A, et al. 
Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants 
and by a DMBT1 variant which influences binding of the transcription factors CREB1 and 
ATF-2. PloS one. 2013;8(11):e77773.  
Excluded by title 
59 
Duran-Pinedo AE, Paster B, Teles R, Frias-Lopez J. Correlation network analysis applied 
to complex biofilm communities. PloS one. 2011;6(12):e28438. Epub 2011/12/14. 
Excluded by title 
60 
Elias MK, Mateen FJ, Weiler CR. The Melkersson-Rosenthal syndrome: a retrospective 
study of biopsied cases. Journal of neurology. 2013;260(1):138-43. Epub 2012/07/28. 
Excluded by title 
61 
Folwaczny M, Glas J, Torok HP, Limbersky O, Folwaczny C. Toll-like receptor (TLR) 2 
and 4 mutations in periodontal disease. Clinical and experimental immunology. 
2004;135(2):330-5. Epub 2004/01/24. 
Excluded by title 
62 
Fry L, Baker BS, Powles AV, Fahlen A, Engstrand L. Is chronic plaque psoriasis triggered 
by microbiota in the skin? The British journal of dermatology. 2013;169(1):47-52. Epub 
2013/03/26. 
Excluded by title 
63 
Garrido-Mesa N, Zarzuelo A, Galvez J. Minocycline: far beyond an antibiotic. British 
journal of pharmacology. 2013;169(2):337-52. Epub 2013/02/28. 
Excluded by title 
64 
Glade MJ. Vitamin D: health panacea or false prophet? Nutrition (Burbank, Los Angeles 
County, Calif). 2013;29(1):37-41. Epub 2012/10/23. 
Excluded by title 
65 
Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nature 
reviews Microbiology. 2012;10(10):717-25. Epub 2012/09/04. 
Excluded by title 
66 
Healy CM, Farthing PM, Williams DM, Thornhill MH. Pyostomatitis vegetans and 
associated systemic disease. A review and two case reports. Oral surgery, oral medicine, 
and oral pathology. 1994;78(3):323-8.  
Excluded by title 
67 
Hofstad T. Immune responses to anaerobic gram-negative bacteria in health and disease. 
Die Nahrung. 1984;28(6-7):717-21. Epub 1984/01/01. 
Excluded by title 
68 
Ichiishi S, Tanaka K, Nakao K, Izumi K, Mikamo H, Watanabe K. First isolation of 
Desulfovibrio from the human vaginal flora. Anaerobe. 2010;16(3):229-33. Epub 
2010/02/18. 
Excluded by title 
69 
Ingram C. Melkersson-Rosenthal syndrome or oro-facial granulomatosis (OFG): an 
update. Journal of the New Zealand Society of Periodontology. 1999(84):24-5. Epub 
2000/05/24. 
Excluded by title 
70 
Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M. Metatranscriptomics of 
the human oral microbiome during health and disease. mBio. 2014;5(2):e01012-14. Epub 
2014/04/03. 
Excluded by title 
71 
Kaakoush NO, Mitchell HM. Campylobacter concisus - A new player in intestinal disease. 
Frontiers in cellular and infection microbiology. 2012;2:4. Epub 2012/08/25. 
Excluded by title 
72 
Kuehbacher T, Rehman A, Lepage P, Hellmig S, Folsch UR, Schreiber S, et al. Intestinal 
TM7 bacterial phylogenies in active inflammatory bowel disease. Journal of medical 
microbiology. 2008;57(Pt 12):1569-76.  
Excluded by title 
73 
Kverka M, Tlaskalova-Hogenova H. Two faces of microbiota in inflammatory and 
autoimmune diseases: triggers and drugs. APMIS : acta pathologica, microbiologica, et 
Excluded by title 
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immunologica Scandinavica. 2013;121(5):403-21. 
74 
Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous 
disorders and on response to drugs. Current drug metabolism. 2008;9(6):532-7. Epub 
2008/08/06. 
Excluded by title 
75 
Lakschevitz FS, Glogauer M. High-purity neutrophil isolation from human peripheral blood 
and saliva for transcriptome analysis. Methods in molecular biology (Clifton, NJ). 
2014;1124:469-83. Epub 2014/02/08. 
Excluded by title 
76 
Lazaro P. [Oral rehabilitation of a patient with Crohn's disease]. Le Chirurgien-dentiste de 
France. 1990;60(544-545):57-64. Epub 1990/12/20. Rehabilitation buccale chez un sujet 
atteint de maladie de Crohn. 
Excluded by title 
77 
Lodowska J, Wolny D, Jaworska-Kik M, Kurkiewicz S, Dzierzewicz Z, Weglarz L. The 
chemical composition of endotoxin isolated from intestinal strain of Desulfovibrio 
desulfuricans. TheScientificWorldJournal. 2012;2012:647352. Epub 2012/05/26. 
Excluded by title 
78 
Loos BG, Fiebig A, Nothnagel M, Jepsen S, Groessner-Schreiber B, Franke A, et al. 
NOD1 gene polymorphisms in relation to aggressive periodontitis. Innate immunity. 
2009;15(4):225-32. Epub 2009/07/10. 
Excluded by title 
79 
Nibali L, Donos N, Henderson B. Periodontal infectogenomics. Journal of medical 
microbiology. 2009;58(Pt 10):1269-74. Epub 2009/06/17. 
Excluded by title 
80 
Ogawa T, Tarkowski A, McGhee ML, Moldoveanu Z, Mestecky J, Hirsch HZ, et al. 
Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic 
inflammatory tissue. Journal of immunology (Baltimore, Md : 1950). 1989;142(4):1150-8. 
Epub 1989/02/15. 
Excluded by title 
81 
Pagoldh M, Lange S, Jennische E, Almer S, Bostrom EA, Eriksson A. Faecal analysis and 
plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis 
are predictive of the need for colectomy. European journal of gastroenterology & 
hepatology. 2014;26(3):295-300. Epub 2014/01/15. 
Excluded by title 
82 
Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic 
intervention. Nature reviews Drug discovery. 2012;11(3):234-50. Epub 2012/03/02. 
Excluded by title 
83 
Rees TD. Orofacial granulomatosis and related conditions. Periodontol 2000. 
1999;21:145-57. Epub 1999/11/07. 
Excluded by title 
84 
Reismann P, Racz K, Tulassay Z. [Polymorphisms of the Toll-like receptor 4 gene and 
their potential role in infectious diseases and chronic inflammatory disorders]. Orvosi 
hetilap. 2008;149(38):1791-9. Epub 2008/09/23. A Toll-like receptor-4-
genpolimorfizmusok, valamint lehetseges klinikai szerepuk fertozesekben es kronikus 
gyulladasos betegsegekben. 
Excluded by title 
85 
Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, et al. Alterations 
in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to 
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Appendix S4 Results of the individual outcomes from the included studies that were not included in meta-analyses. 
 
    IBD vs control CD vs control UC vs control 
Outcome Study MD (95% CI) P MD (95% CI) P MD (95% CI) P 
SG shallow pockets: IL-4 Barros 2007 -0.85 (-1.71,0.01) 0.052 -0.50 (-1.47,0.47) 0.312 -1.20 (-2.04,-0.36) 0.005 
Serum IFN-γ Barros 2007 0.00 (-0.16,0.16) 1.000 0.00 (-0.17,0.17) 1.000 0.00 (-0.15,0.15) 1.000 
Serum IL-10 Barros 2007 -1.80 (-11.37,7.77) 0.712 -3.40 (-11.32,4.52) 0.400 -0.30 (-13.55,12.95) 0.965 
Serum IL-12p70 Barros 2007 0.00 (-1.24,1.24) 1.000 0.00 (-1.24,1.24) 1.000 0.00 (-1.24,1.24) 1.000 
Serum IL-18 Barros 2007 50.71 (10.26,91.16) 0.014 48.90 (-4.31,102.11) 0.072 52.40 (3.77,101.03) 0.035 
Serum IL-4 Barros 2007 0.00 (-4.56,4.56) 1.000 0.00 (-4.44,4.44) 1.000 0.00 (-5.65,5.65) 1.000 
Serum IL-6 Barros 2007 0.71 (-7.12,8.54) 0.859 0.40 (-7.60,8.40) 0.922 1.00 (-6.90,8.90) 0.804 
SG deep pockets: %PI Barros 2007 -5.45 (-29.21,18.31) 0.653 -0.50 (-27.25,26.25) 0.971 -10.40 (-37.79,16.99) 0.457 
SG deep pockets: CAL Barros 2007 0.40 (-0.69,1.49) 0.470 0.60 (-0.85,2.05) 0.417 0.20 (-0.88,1.28) 0.717 
SG deep pockets: GCF volume Barros 2007 0.35 (-0.36,1.06) 0.337 0.30 (-0.45,1.05) 0.434 0.40 (-0.54,1.34) 0.405 
SG deep pockets: IFN-γ Barros 2007 0.00 (-0.05,0.05) 1.000 0.00 (-0.08,0.08) 1.000 0.00 (-0.08,0.08) 1.000 
SG deep pockets: IL-18 Barros 2007 4.85 (-8.59,18.29) 0.479 2.70 (-11.88,17.28) 0.717 7.00 (-7.72,21.72) 0.351 
SG deep pockets: IL-1b Barros 2007 1.00 (-0.35,2.35) 0.147 1.20 (-0.21,2.61) 0.095 0.80 (-1.39,2.99) 0.473 
SG deep pockets: IL-4 Barros 2007 -0.95 (-1.99,0.09) 0.074 -1.00 (-2.05,0.05) 0.061 -0.90 (-2.07,0.27) 0.130 
SG deep pockets: IL-6 Barros 2007 0.15 (-0.09,0.39) 0.212 0.00 (-0.36,0.36) 1.000 0.30 (0.05,0.55) 0.018 
SG deep pockets: PPD Barros 2007 -0.05 (-0.92,0.82) 0.911 -0.10 (-1.14,0.94) 0.850 0.00 (-0.91,0.91) 1.000 
SG gingivitis: P.a. Barros 2007 0.16 (-0.04,0.36) 0.121 0.37 (0.08,0.66) 0.013 -0.05 (-0.24,0.14) 0.597 
SG gingivitis: Pa.m. Barros 2007 0.05 (-0.51,0.61) 0.860 0.49 (-0.23,1.21) 0.181 -0.40 (-0.93,0.13) 0.137 
SG gingivitis: Pr.m. Barros 2007 0.49 (0.10.0.88) 0.014 0.97 (0.45,1.49) <0.001 0.01 (-0.34,0.36) 0.955 
SG gingivitis: Sta.a Barros 2007 0.75 (0.27,1.23) 0.002 1.40 (0.79,2.01) <0.001 0.10 (-0.43,0.63) 0.710 
SG gingivitis: Str.a. Barros 2007 0.29 (-0.01,0.59) 0.060 0.68 (0.18,1.18) 0.007 -0.10 (-0.25,0.05) 0.192 
SG gingivitis: Str.mi. Barros 2007 0.08 (-0.20,0.36) 0.574 0.34 (-0.08,0.76) 0.113 -0.19 (-0.38,0.00) 0.051 
SG gingivitis: Str.mu. Barros 2007 0.19 (-0.20,0.58) 0.342 0.49 (-0.17,1.15) 0.144 -0.11 (-0.36,0.14) 0.378 
SG gingivitis: Tr.d. Barros 2007 0.21 (-0.08,0.50) 0.151 0.39 (-0.09,0.87) 0.108 0.02 (-0.17,0.21) 0.833 
SG non-smokers: BOP Barros 2007 -2.80 (-9.05,3.45) 0.380 -3.40 (-10.00,3.20) 0.313 -1.80 (-8.98,5.38) 0.623 
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SG non-smokers: CAL Barros 2007 0.11 (-0.12,0.34) 0.356 0.00 (-0.23,0.23) 1.000 0.30 (-0.07,0.67) 0.116 
SG non-smokers: CAL>3 Barros 2007 3.07 (-3.36,9.50) 0.349 1.30 (-4.65,7.25) 0.668 6.00 (-4.79,16.79) 0.276 
SG non-smokers: DMFT Barros 2007 1.77 (-0.53,4.07) 0.131 0.90 (-1.60,3.40) 0.480 3.20 (0.29,6.11) 0.031 
SG non-smokers: no of teeth Barros 2007 -1.38 (-3.16,0.40) 0.128 -1.00 (-3.01,1.01) 0.330 -2.00 (-4.62,0.62) 0.135 
SG non-smokers: PI Barros 2007 -13.90 (-24.78,-3.02) 0.012 -14.20 (-24.97,-3.44) 0.010 -13.40 (-33.12,6.32) 0.183 
SG non-smokers: PPD Barros 2007 0.86 (0.72,1.00) <0.001 0.90 (0.69,1.11) <0.001 0.80 (0.71,0.89) <0.001 
SG periodontitis: B.u. Barros 2007 0.17 (0.07,0.27) 0.001 0.30 (0.16,0.44) <0.001 0.03 (-0.05,0.11) 0.457 
SG periodontitis: C.g. Barros 2007 0.22 (-0.06,0.50) 0.127 0.44 (0.09,0.79) 0.014 -0.01 (-0.30,0.28) 0.946 
SG periodontitis: P.m. Barros 2007 0.42 (-0.00,0.84) 0.052 0.86 (0.22,1.50) 0.009 -0.02 (-0.32,0.28) 0.896 
SG periodontitis: S.ang. Barros 2007 0.35 (0.06,0.64) 0.018 0.77 (0.36,1.18) <0.001 -0.07 (-0.26,0.12) 0.459 
SG periodontitis: S.aur. Barros 2007 0.40 (-0.06,0.86) 0.091 0.83(0.16,1.50) 0.015 -0.04 (-0.39,0.31) 0.823 
SG periodontitis: S.int. Barros 2007 0.21 (0.01,0.42) 0.044 0.43 (0.14,0.72) 0.004 -0.01 (-0.18,0.16) 0.906 
SG periodontitis: S.mit. Barros 2007 0.16 (-0.06,0.38) 0.145 0.34 (0.07,0.61) 0.012 -0.03 (-0.23,0.17) 0.766 
SG periodontitis: S.mut. Barros 2007 0.22 (-0.13,0.57) 0.218 0.54 (0.04,1.04) 0.033 -0.10 (-0.37,0.17) 0.468 
SG shallow pockets: CAL Barros 2007 -0.25 (-0.37,-0.13) <0.001 -0.30 (-0.46,-0.14) <0.001 -0.20 (-0.36,-0.04) 0.014 
SG shallow pockets: GCF volume Barros 2007 0.05 (-0.50,0.60) 0.859 0.10 (-0.51,0.71) 0.748 0.00 (-0.73,0.73) 1.000 
SG shallow pockets: IFN-γ Barros 2007 0.00 (-0.05,0.05) 1.000 0.00 (-0.08,0.08) 1.000 0.00 (-0.08,0.08) 1.000 
SG shallow pockets: IL-18 Barros 2007 -7.75 (-24.54,9.04) 0.365 -10.70 (-27.33,5.93) 0.207 -4.80 (-23.08,13.48) 0.607 
SG shallow pockets: IL-1b Barros 2007 -0.65 (-1.47,0.17) 0.122 -0.80 (-1.69,0.09) 0.079 -0.50 (-1.39,0.39) 0.272 
SG shallow pockets: IL-6 Barros 2007 0.00 (-0.13,0.13) 1.000 0.00 (-0.00,0.00) 1.000 0.00 (-0.26,0.26) 1.000 
SG shallow pockets: PI Barros 2007 -21.60 (-44.76,1.56) 0.068 -26.00 (-54.59,2.59) 0.075 -17.20 (-43.47,9.07) 0.199 
SG shallow pockets: PPD Barros 2007 -0.25 (-0.41,-0.09) 0.002 -0.20 (-0.38,-0.02) 0.032 -0.30 (-0.53,-0.07) 0.009 
SG smokers: BOP Barros 2007 -5.87 (-15.93,4.19) 0.253 -7.70 (-18.38,2.98) 0.157 -4.30 (-15.22,6.62) 0.440 
SG smokers: CAL Barros 2007 -0.03 (-0.54,0.48) 0.907 -0.30 (-0.83,0.23) 0.265 0.20 (-0.35,0.75) 0.479 
SG smokers: CAL>3 Barros 2007 5.19 (-9.72,20.10) 0.495 0.40 (-15.09,15.89) 0.960 9.30 (-6.60,25.20) 0.252 
SG smokers: DMFT Barros 2007 4.10 (1.38,6.82) 0.003 4.80 (1.67,7.93) 0.003 3.50 (0.51,6.49) 0.022 
SG smokers: no of teeth Barros 2007 -1.88 (-4.26,0.50) 0.121 0.00 (-3.19,3.19) 1.000 -3.50 (-6.01,-0.99) 0.006 
SG smokers: PI Barros 2007 -12.96 (-29.87,3.95) 0.133 -13.50 (-32.09,5.09) 0.155 -12.50 (-31.25,6.25) 0.191 
SG smokers: PPD Barros 2007 0.41 (0.14,0.68) 0.003 0.30 (-0.17,0.77) 0.210 0.50 (0.29,0.71) <0.001 
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TNFα Barros 2007 -0.82 (-2.73,1.09) 0.400 -0.30 (-2.43,1.83) 0.783 -1.30 (-3.26,0.66) 0.194 
DMFS Groessner 2006 7.60 (-2.77,17.97) 0.151 - - - - 
Furcation involvement Groessner 2006 7.90 (-3.82,19.62) 0.186 - - - - 
CAL>4 Habasneh 2012 15.66 (10.41,20.91) <0.001 12.25 (4.76,19.74) 0.001 17.65 (11.23,24.07) <0.001 
CAL>5 Habasneh 2012 3.51 (1.58,5.44) <0.001 0.03 (-2.12,2.18) 0.978 5.55 (2.86,8.24) <0.001 
GI Habasneh 2012 0.94 (0.77,1.11) <0.001 0.88 (0.66,1.10) <0.001 0.97 (0.79,1.15) <0.001 
GR Habasneh 2012 0.30 (0.14,0.46) <0.001 0.09 (-0.09,0.27) 0.335 0.42 (0.24,0.60) <0.001 
SG gingivitis: CAL Rathnayake 2008 -0.15 (-0.31,0.01) 0.064 -0.30 (-0.50,-0.10) 0.004 0.00 (-0.20,0.20) 1.000 
SG gingivitis: GCF Rathnayake 2008 0.05 (-0.36,0.46) 0.809 0.10 (-0.35,0.55) 0.664 0.00 (-0.54,0.54) 1.000 
SG gingivitis: PPD Rathnayake 2008 -0.40 (-0.64,-17) 0.001 -0.30 (-0.54,-0.06) 0.015 -0.50 (-0.84,-0.17) 0.003 
SG gingivitis: VPI Rathnayake 2008 -45.00 (-75.18,-14.82) 0.003 -50.00 (-91.91,-8.09) 0.019 -40.00 (-75.37,-4.64) 0.027 
SG periodontitis: CAL Rathnayake 2008 0.85 (0.14,1.56) 0.019 0.70 (-0.41,1.81) 0.216 1.00 (0.36,1.64) 0.002 
SG periodontitis: GCF Rathnayake 2008 0.35 (-0.18,0.88) 0.194 0.30 (-0.26,0.86) 0.290 0.40 (-0.30,1.10) 0.260 
SG periodontitis: PPD Rathnayake 2008 0.20 (-0.27,0.67) 0.406 0.20 (-0.44,0.84) 0.538 0.20 (-0.37,0.77) 0.492 
SG periodontitis: VPI Rathnayake 2008 -11.65 (-46.29,22.99) 0.510 -8.30 (-48.06,31.46) 0.682 -15.00 (-56.11,26.11) 0.475 
D(ecayed) index Slebioda 2011 1.57 (0.91,2.23) <0.001 1.70 (0.90,2.50) <0.001 1.20 (0.31,2.09) 0.008 
Dental caries treatment index Slebioda 2011 -0.15 (-0.24,-0.06) 0.002 -0.18 (-0.28,-0.08) 0.000 -0.08 (-0.23,0.07) 0.308 
Fillings Slebioda 2011 -0.20 (-1.57,1.17) 0.775 -0.20 (-1.67,1.27) 0.790 -0.20 (-2.24,1.84) 0.848 
M(issing) index Slebioda 2011 5.37 (3.41,7.33) <0.001 5.40 (3.16,7.65) <0.001 5.30 (1.81,8.79) 0.003 
Oral hygiene index Slebioda 2011 1.24 (0.99,1.49) <0.001 1.40 (1.14,1.66) <0.001 0.80 (0.41,1.19) <0.001 
Bleeding in deepest tooth Vavricka 2013 0.12 (0.03,0.21) 0.012 0.16 (0.04,0.28) 0.008 0.05 (-0.07,0.17) 0.406 
CAL in deepest tooth Vavricka 2013 0.43 (0.11,0.75) 0.009 0.43 (0.04,0.83) 0.033 0.44 (-0.01,0.89) 0.055 
Papilla bleeding index Vavricka 2013 0.23 (0.12,0.34) <0.001 0.23 (0.11,0.35) <0.001 0.22 (0.03,0.41) 0.023 
                
Outcome Study OR (95% CI) P OR (95% CI) P OR (95% CI) P 
CAL>4 Groessner 2006 2.30 (1.01,5.26) 0.048 - - - - 
CAL>5 Groessner 2006 2.01 (0.97,4.16) 0.060 - - - - 
Dentine caries Groessner 2006 2.39 (1.08,5.31) 0.032 - - - - 
Atrophic tongue Slebioda 2011 13.70 (0.78,241.42) 0.074 19.18 (1.09,339.03) 0.044 - - 
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Candida Slebioda 2011 3.09 (1.62,5.87) 0.001 3.24 (1.62,6.47) 0.001 2.70 (1.06,6.90) 0.038 
Candida + Slebioda 2011 0.98 (0.46,2.08) 0.953 0.84 (0.37,1.92) 0.673 1.43 (0.50,4.05) 0.505 
Candida ++ Slebioda 2011 1.30 (0.48,3.50) 0.601 1.68 (0.61,4.62) 0.316 0.38 (0.04,3.21) 0.371 
Candida +++ Slebioda 2011 7.13 (2.05,24.86) 0.002 6.62 (1.83,23.90) 0.004 8.69 (2.04,36.99) 0.003 
Candida wz Slebioda 2011 8.57 (0.47,157.58) 0.148 11.84 (0.64,218.33) 0.097 - - 
Complete dentition Slebioda 2011 0.18 (0.09,0.35) <0.001 0.19 (0.09,0.39) <0.001 0.15 (0.05,0.44) 0.001 
CPITN 2-3 Slebioda 2011 4.10 (2.13,7.89) <0.001 4.20 (2.07,8.52) <0.001 3.83 (1.45,10.11) 0.007 
CPITN 0-1 Slebioda 2011 0.18 (0.09,0.35) <0.001 0.15 (0.07,0.32) <0.001 0.26 (0.10,0.69) 0.007 
Dark indelible patches Slebioda 2011 0.48 (0.08,2.95) 0.429 0.32 (0.03,3.19) 0.334 0.93 (0.09,9.38) 0.951 
Deaquamative cheilitis Slebioda 2011 1.11 (0.18,6.82) 0.911 1.00 (0.14,7.31) 1.000 1.42 (0.12,16.34) 0.780 
Edentia Slebioda 2011 6.93 (0.37,130.94) 0.196 9.54 (0.50,180.64) 0.133 - - 
Fissured tongue Slebioda 2011 3.03 (0.33,27.75) 0.326 3.09 (0.31,30.45) 0.334 2.88 (0.17,47.78) 0.461 
Fordyce’s spots Slebioda 2011 1.31 (0.37,4.67) 0.675 1.00 (0.24,4.17) 1.000 2.25 (0.47,10.85) 0.312 
Geographic tongue Slebioda 2011 1.89 (0.36,10.03) 0.455 2.06 (0.37,11.63) 0.413 1.42 (0.12,16.34) 0.780 
Linea alba Slebioda 2011 0.19 (0.09,0.40) <0.001 0.20 (0.09,0.45) <0.001 0.16 (0.04,0.59) 0.006 
Palatal erythema Slebioda 2011 2.05 (0.53,8.04) 0.301 2.88 (0.73,11.35) 0.130 0.38 (0.02,7.58) 0.525 
Palatal papillary hyperplasia Slebioda 2011 2.24 (0.09,55.76) 0.623 3.04 (0.12,75.99) 0.498 - - 
Recurrent aphthous stomatitis Slebioda 2011 4.24 (1.64,10.93) 0.003 3.97 (1.48,10.68) 0.006 5.02 (1.53,16.43) 0.008 
Recurrent labial herpes Slebioda 2011 0.36 (0.06,1.99) 0.240 0.49 (0.09,2.74) 0.413 0.29 (0.02,5.58) 0.412 
Rhomboid glossitis Slebioda 2011 6.93 (0.37,130.94) 0.196 9.54 (0.50,180.64) 0.133 - - 
Sound teeth Slebioda 2011 0.31 (0.16,0.59) <0.001 0.27 (0.14,0.55) <0.001 0.42 (0.17,1.08) 0.071 
Swollen buccal mucosa Slebioda 2011 7.98 (2.30,27.66) 0.001 10.24 (2.90,36.16) <0.001 3.05 (0.57,16.20) 0.192 
Teeth with radicular or coronal decay Slebioda 2011 3.27 (1.71,6.27) <0.001 3.69 (1.83,7.43) <0.001 2.36 (0.93,6.01) 0.071 
White coated tongue Slebioda 2011 1.62 (0.87,3.03) 0.132 1.50 (0.77,2.95) 0.234 2.01 (0.77,5.25) 0.156 
White indelible patches and plates Slebioda 2011 3.83 (0.44,33.57) 0.225 1.00 (0.06,16.31) 1.000 13.14 (1.39,124.09) 0.025 
Buccal swelling Zervou 2004 4.83 (0.19,122.53) 0.340 9.83 (0.38,254.52) 0.169 - - 
Buccal trauma Zervou 2004 41.98 (2.34,754.61) 0.011 65.00 (3.37,1253.85) 0.006 26.60 (1.29,549.44) 0.034 
Cobblestoning Zervou 2004 12.09 (0.60,242.89) 0.103 26.60 (1.29,549.44) 0.034 - - 
Erythema migrans Zervou 2004 4.83 (0.19,122.53) 0.340 9.83 (0.38,254.52) 0.169 - - 
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Fissures elsewhere Zervou 2004 12.09 (0.60,242.89) 0.103 26.60 (1.29,549.44) 0.034 - - 
Fissures lip Zervou 2004 0.33 (0.10,1.11) 0.073 0.33 (0.07,1.64) 0.175 0.33 (0.07,1.64) 0.175 
Fissures medline Zervou 2004 0.14 (0.03,0.66) 0.013 0.30 (0.06,1.49) 0.140 0.06 (0.00,1.10) 0.058 
Gingival bleeding Zervou 2004 16.13 (0.84,311.36) 0.066 37.17 (1.87,740.64) 0.018 - - 
Gingivitis Zervou 2004 16.13 (0.84,311.36) 0.066 26.60 (1.29,549.44) 0.034 9.83 (0.38,254.52) 0.169 
Leukoplakia Zervou 2004 4.83 (0.19,122.53) 0.340 9.83 (0.38,254.52) 0.169 - - 
Lip swelling Zervou 2004 16.13 (0.84,311.36) 0.066 26.60 (1.29,549.44) 0.034 9.83 (0.38,254.52) 0.169 
Lymphadenopathy Zervou 2004 48.66 (2.72,870.23) 0.008 83.82 (4.37,1 608.44) 0.003 26.60 (1.29,549.44) 0.034 
Polypoid tags Zervou 2004 12.09 (0.60,242.89) 0.103 26.60 (1.29,549.44) 0.034 - - 
Salivary gland involvement Zervou 2004 16.13 (0.84,311.36) 0.066 - - 37.17 (1.87,740.64) 0.018 
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; MD, mean difference; CI, confidence interval; SG, subgroup; IL, interleukin; 
IFN, interferon; PI, plaque index; CAL, clinical attachment level; GCF; gingival crevicular fluid; PPD, pocket probing depth; P.a., Peptostreptococcus 
anaerobius; Pa.m., Parvimonas micra; Pr.m., Prevotella melaninogenica; Sta.a., Staphylococcus aureus; Str.a., Streptococcus anginosus; Str.mi., 
Streptococcus mitis; Str.mu., Streptococcus mutans; Tr.d., Treponema denticola; BOP, bleeding on probing; DMFT, decayed missing filled teeth; B.u., 
Bacteroides ureolyticus; C.g., Campylobacter gracilis; P.m., P. melaninogenica; S.ang., S. anginosus; S.aur., S. aureus; S.int., S. intermedius; S.mit., S. mitis; 
S.mut., S. mutans; TNF, tumor necrosis factor; DMFS, decayed missing filled tooth surfaces; GI, gingival index; GR, gingival recession; VPI, visible plaque 
index; OR, odds ratio; CPITN, community periodontal index treatment need. 
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Appendix S5. Forest plot with the meta-analyses regarding the number of teeth. IBD, inflammatory bowel disease; n, sample; SD, standard deviation; MD, 
mean difference; CI, confidence interval; PrI, predictive interval; CD, Crohn’s disease; UC, ulcerative colitis. 
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Appendix S6. Forest plot with the meta-analyses regarding the DMFT index. DMFT, decayed missing filled teeth; IBD, inflammatory bowel disease; n, 
sample; SD, standard deviation; MD, mean difference; CI, confidence interval; PrI, predictive interval; CD, Crohn’s disease; UC, ulcerative colitis. 
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Appendix S7. Results of Meta-Analyses Comparing Patients With Crohn’s Disease Compared to Healthy Patients 
 
  Effect size  Heterogeneity 
Outcome Studies MD or OR (95% CI) p 95% PrI 
 
I2 (95% CI) τ2 
Primary outcome        
Periodontitis 4 OR: 3.96 (2.39,6.54) <0.001 1.31,11.92  0 (0,68) 0 
        
Secondary outcomes        
Number of teeth 3 MD: -0.11 (-1.52,1.31) 0.881 -13.40,13.18 
 
36 (0,82) 0.572 
DMFT index 3* MD: 3.73 (0.70,6.75) 0.016 -32.75,40.20 
 
82 (0,92) 5.863 
Plaque index c 
      
Bleeding on probing a 
      
Clinical attachment loss b 
      
Clinical attachment loss > 3mm 2 MD: 2.42 (-2.49,7.33) 0.333 NA 
 
0 (NA) 0 
Pocket probing depth 3* MD: 0.56 (-0.01,1.13) 0.054 -6.67,7.79 
 
95 (90,97) 0.239 
Pocket probing depth > 3mm 2 MD: 4.82 (0.65,8.99) 0.024 NA 
 
0 (NA) 0 
Pocket probing depth > 4mm 3* MD: -3.49 (-9.41,2.43) 0.248 -73.87,66.89 
 
90 (67,95) 21.550 
Oral lesions 2* OR: 5.17 (0.53,50.58) 0.158 NA 
 
96 (NA) 2.590 
Angular cheilitis 2 OR: 10.04 (0.85,118.26) 0.067 NA 
 
56 (NA) 1.877 
Aphthous lesions 2 OR: 1.99 (0.56,7.08) 0.289 NA  74 (NA) 0.626 
Hairy tongue 2 OR: 9.44 (1.07,83.01) 0.043 NA  0 (NA) 0 
Ulceration 2 OR: 11.16 (1.30,95.55) 0.028 NA  0 (NA) 0 
MD, mean difference; OR, odds ratio; CI, confidence interval; PrI, predictive interval; NA, not applicable; DMFT, decayed missing filling teeth. 
*extreme heterogeneity, but agrees on direction; effect magnitude might be misestimated. 
a Meta-analysis omitted; three studies with extreme heterogeneity; studies evenly distributed (MD=1.65; 95% CI=-7.06,10.37; p=0.710; I2=77) 
b Meta-analysis omitted; three studies with extreme heterogeneity; studies evenly distributed (MD=0.013; 95% CI=-0.42,0.45; p=0.954; I2=78) 
c Meta-analysis omitted; three studies with extreme heterogeneity; studies evenly distributed (Standardized Mean Difference=-0.05; 95% CI=-0.77,0.67; 
p=0.891; I2=90)  
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Appendix S8. Results of Meta-Analyses Comparing Patients With Ulcerative Colitis Compared to Healthy Patients 
 
  Effect size  Heterogeneity 
Outcome Studies MD or OR (95% CI) p 95% PrI 
 
I2 (95% CI) τ2 
Primary outcome        
Periodontitis 3 OR: 5.11 (2.92,8.92) <0.001 0.14,189.85 
 
0 (0,73) 0 
        
Secondary outcomes 
       
Number of teeth 3 MD: -1.86 (-3.68,-0.04) 0.045 -19.78,16.06 
 
44 (0,83) 1.128 
DMFT index 3 MD: 3.97 (1.94,6.00) <0.001 -16.08,24.04 
 
44 (0,83) 1.420 
Plaque index 2a,* MD: 0.50 (-0.42,1.41) 0.289 NA 
 
95 (NA) 0.415 
Bleeding on probing 3 MD: 1.42 (-5.01,7.86) 0.665 -69.58,72.43 
 
67 (0,88) 20.444 
Clinical attachment loss 3 MD: 0.40 (-0.02,0.828) 0.061 -4.40,5.21 
 
74 (0,90) 0.096 
Clinical attachment loss > 3mm 2 MD: 13.68 (7.29,20.08) <0.001 NA 
 
7 (NA) 1.515 
Pocket probing depth 3* MD: 0.66 (0.27,1.05) 0.001 -4.22,5.54 
 
96 (91,97) 0.108 
Pocket probing depth > 3mm 2 MD: 0.55 (-10.43,11.54) 0.921 NA 
 
64 (NA) 44.715 
Pocket probing depth > 4mm b 
      
Oral lesions 2* OR: 6.27 (1.53,25.70) 0.011 NA 
 
87 (NA) 0.906 
Angular cheilitis 2 OR: 4.54 (0.07,288.50) 0.476 NA 
 
73 (NA) 6.588 
Aphthous lesions 3 OR: 3.38 (1.75,6.53) <0.001 0.05,242.46  0 (0,73) 0 
Hairy tongue 2 OR: 9.21 (0.93,91.25) 0.058 NA  0 (NA) 0 
Ulceration 2 OR: 9.21 (0.93,91.25) 0.058 NA  0 (NA) 0 
MD, mean difference; OR, odds ratio; CI, confidence interval; PrI, predictive interval; NA, not applicable; DMFT, decayed missing filling teeth. 
*extreme heterogeneity, but agrees on direction; effect magnitude might be misestimated. 
a Omitted study of Rathnayake 2008 to achieve homogeneity (Standardized Mean Difference (SMD) =0.29; 95% CI=-0.47,1.04; p=0.460; I2=91); used SMD to 
combine two plaque indeces 
b Meta-analysis omitted; three studies with extreme heterogeneity; studies evenly distributed (MD=-1.73; 95% CI=-5.78,2.33; p=0.404; I2=75) 
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Appendix S9. Additional details about the Summary of Findings table (Table 4). 
 
Outcome 
Risk of 
Bias 
Inconsistency Indirectness Imprecision Publication bias Large Effect 
Dose 
Response 
Residual Confounding 
Periodontitis 
IBD 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
Rated up by two levels for very 
large effect included in the 
confidence and predictive 
interval. 
No reason 
to rate up 
Rated up by one; estimates 
adjusted for confounders 
confirmed results agree with 
original analyses. 
Periodontitis 
CD 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
Rated up by one level for large 
effect included in the 
confidence and predictive 
interval. 
No reason 
to rate up 
Rated up by one; estimates 
adjusted for confounders 
confirmed results agree with 
original analyses. 
Periodontitis 
UC 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
Rated up by two levels for very 
large effect included in the 
confidence and predictive 
interval. 
No reason 
to rate up 
Rated up by one; estimates 
adjusted for confounders 
confirmed results agree with 
original analyses. 
No of teeth IBD 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
No of teeth CD 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
No of teeth UC 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
DMFT IBD 
No 
serious 
limitations 
Extreme 
heterogeneity; 
however effects agree 
in direction and 
confidence regarding 
decision is unaffected; 
no apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
DMFT CD 
No 
serious 
limitations 
Extreme 
heterogeneity; 
however effects agree 
in direction and 
confidence regarding 
decision is unaffected; 
no apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
DMFT UC 
No 
serious 
limitations 
Little to no 
heterogeneity; no 
apparent reason to 
downgrade. 
Directly relevant; 
no apparent 
reason to 
downgrade. 
Adequate sample; no 
apparent reason to 
downgrade. 
Small number of studies 
precluded formal assessment 
of reporting bias; no apparent 
reason to downgrade. 
No reason to rate up 
No reason 
to rate up 
No reason to rate up 
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; DMFT, decayed-missing-filled-teeth index. 
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Appendix S10. Exploratory comparison of differences between UC and CD patients (UC minus CD). 
 
  
Effect size 
 
Heterogeneity 
Outcome Studies MD or OR (95% CI) P 95% PrI 
 
I2 (95% CI) τ2 
Primary outcome 
       
Periodontitis 2 OR: 0.86 (0.11,6.58) 0.884 NA 
 
44 (NA) 1.129 
        
Secondary outcomes 
       
Number of teeth 4 MD: -1.67 (-2.97,-0.34) 0.013 -10.68,7.41 
 
0 (0,73) 0 
DMFT index 3 MD: 0.69 (-0.81,2.20) 0.365 -9.05,10.44 
 
0 (0,73) 0 
Plaque index 3 SMD: 0.33 (0.13,0.54) 0.002 -1.02,1.69 
 
0 (0,73) 0 
Bleeding on probing 3 MD: 0.41 (-2.91,3.72) 0.811 -21.09,21.90 
 
0 (0,73) 0 
Clinical attachment loss 3 MD: 0.40 (0.20,0.59) <0.001 -0.89,1.68 
 
0 (0,73) 0 
Clinical attachment loss > 3mm 2 MD: 10.18 (4.10,16.25) <0.001 NA 
 
0 (0,73) 0 
Pocket probing depth 3 MD: 0.12 (-0.03,0.28) 0.124 -1.33,1.58 
 
33 (0,81) 0.001 
Pocket probing depth > 3mm *       
Pocket probing depth > 4mm 3 MD: 1.33 (-0.80,3.45) 0.220 -21.64,24.30 
 
69 (0,89) 2.092 
Angular cheilitis 2 OR: 0.52 (0.13,2.07) 0.354 NA 
 
0 (NA) 0 
Aphthous lesions 3 OR: 1.86 (0.97,3.58) 0.063 0.03,129.72 
 
0 (0,73) 0 
Hairy tongue 2 OR: 0.82 (0.14,4.76) 0.829 NA 
 
0 (NA) 0 
Ulceration 2 OR: 0.68 (0.12,3.71) 0.653 NA 
 
0 (NA) 0 
UC, ulcerative colitis; CD, Crohn’s disease; MD, mean difference; OR, odds ratio; CI, confidence interval; PrI, predictive interval; NA, not applicable; DMFT, 
decayed missing filling teeth. 
* Meta-analysis omitted; two studies with extreme heterogeneity; studies evenly distributed (MD=-0.59; 95% CI=-18.56,17.37; P=0.949; I2=88) 
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Appendix S11. Results of random-effects meta-regression according to patient characteristics. 
 
 Age Sex Smokers Active disease Medication use 
 n Coefficient (95%CI) P n Coefficient (95%CI) P n Coefficient (95%CI) P n Coefficient (95%CI) P n Coefficient (95%CI) P 
Periodontitis 3 -0.66 (-18.59,17.26) 0.720 3 0.43 (-6.93,7.78) 0.594 3 1.59 (-19.73,22.91) 0.517 - - - 3 -0.54 (-32.66,31.58) 0.867 
No of teeth 4 0.01 (-2.61,2.62) 0.992 4 2.66 (-2.41,7.74) 0.152 4 6.15 (-9.18,21.47) 0.226 3 3.50 (-93.22,100.22) 0.726 4 -7.94 (-23.40,7.52) 0.158 
DMFT 3 -1.14 (-6.34,4.06) 0.219 3 0.88 (-68.93,70.70) 0.898 - - - - - - - - - 
n, sample; CI, confidence interval; DMFT, decayed missing filled teeth index. 
 
 27 
Appendix S12. Sensitivity analysis according to the periodontitis definition. 
 
Study Definition of periodontitis 
Barros 2007 “Periodontitis was defined as the presence of at least four sites in different teeth with CAL ≥ 3 mm.” 
Vavricka 2013 “Crude differences regarding risk factors for periodontitis, assessed by the oral health markers LA-PPD for periodontitis…” 
Habasneh 2012 
“Periodontitis was defined as presence of four or more teeth with one site or more having a probing pocket depth ≥ 4 mm and clinical 
attachment level ≥ 3 mm.” 
Zervou 2004 No definition given. 
 
 IBD CD UC  
 OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Original 4.55 (3.00,6.91) <0.001 3.96 (2.39,6.54) <0.001 5.11 (2.92,8.92) <0.001 
Sensitivity analysis 6.07 (2.96) <0.001 4.82 (2.88,8.08) <0.001 3.70 (1.89,7.24) <0.001 
CAL, clinical attachment loss; LA-PPD, loss of attachment at sites with maximal periodontal pocket depth; IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; OR, odds 
ratio. 
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Appendix S13. Criteria used to diagnose Inflammatory Bowel Disease (IBD), Crohn’s Disease (CD), and Ulcerative Colitis (UC). 
 
Nr. Study Diagnosis 
1 Barros 2007 The diagnosis of CD or UC had been established previously by clinical, radiological, endoscopic and histological analyses. 
2 
Groessner-Schreiber 
2006 
The diagnosis of either CD or UC was confirmed by previously established clinical, radiological and endoscopic criteria (type of lesions, 
distribution*), and histological findings also had to be confirmative or compatible with this diagnosis. 
3 Habashneh 2012 The diagnosis of IBD was established by clinical, radiological, endoscopic and histological criteria. 
4 Koutsochristou 2015 The diagnosis of CD or UC was established according to the Porto criteria.34 
4 5 Rathnayake 2008 The diagnosis of either Crohn’s disease (CD) or Ulcerative colitis (UC) was conformed by clinical, radiographic and endoscopic criteria. 
5 6 Slebioda 2011 Not specified. 
6 7 Van Dyke 1986 
IBD patients were defined as those exhibiting a combination of symptoms, including diarrhea, abdominal pain, bleeding, weight loss, 
perianal disease, and arthritis. 
7 8 Vavricka 2013 The diagnosis of CD or UC had been established previously by clinical, radiological, endoscopic, and histological analyses. 
8 9 Zervou 2007 Not specified. 
*Based on Truelove, S. C. & Pena, A. S. (1976) Course and prognosis of Crohn’s disease. Gut 17, 192–201 & Lennard-Jones, J. E. (1989) Classification of 
inflammatory bowel disease. Scandinavian Journal of Gastroenterology 170 (Suppl.), 2–6. 
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Appendix S14. Additional review data 
Author Contributions 
SNP designed the protocol/datasheets, registered the review, designed and performed the literature 
searches, extracted search results, performed study screening, performed study selection, extracted 
data from studies, performed study quality assessment, performed statistical analysis, graded the 
quality of evidence with the GRADE approach, wrote first draft of the manuscript, checked and 
approved all data prior to submission, submitted the paper, and is responsible for the accuracy of the 
results. 
MH checked the protocol/datasheets, performed study selection, extracted data from studies, 
performed study quality assessment, aided in the interpretation of the analyses, contributed to 
manuscript writing, checked and approved all data prior to submission 
AVBN aided in the interpretation of the analyses, contributed to manuscript writing, checked and 
approved all data prior to submission 
AF aided in the interpretation of the analyses, contributed to manuscript writing, checked and 
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Changes to the protocol after initiation 
1. The primary outcome remained the one that was pre-specified; the secondary outcomes were 
decided upon post hoc evaluation of all identified outcomes (giving priority to outcomes 
reported by most studies). As such the title 
2. The SMD was used for one meta-analysis instead of the MD that was originally planned, in 
order to combine two similar plaque indeces. 
3. Many additional outcomes (periodontal progression and response to periodontal treatment), 
as well as analyses (subgroup analyses, reporting bias, sensitivity analyses) were either not 
possible or partly possible to conduct, due to the number and nature of the included studies. 
4. According to bullet’s 1 and 3, the scope and title of the review was changed from a 
periodontitis-based one to a more general oral-health-related one, although as stated in bullet 
1, the primary outcome remained as pre-specified. 
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5. After peer review, the literature searches were updated in January 2017 and the results from 
the new searches were integrated in the revised submission. 
